

ISTH 2020 Virtual Congress

July 12 - 14, 2020

Target Audience

This activity is designed to meet the needs of physicians, physician assistants and other healthcare practitioners.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

SUNDAY, JULY 12 SESSIONS

Plenary - Advances in Gene Therapy and Ethical Aspects

- Discuss the use of gene transfer and gene editing in somatic gene therapy
- Identify the ethical challenges associated with germline gene editing

State-of-the-Art on Hemophilia and Rare Bleeding Disorders

- Discuss the current advances in hemophilia gene therapy
- Review the pathophysiologic basis of immune responses to factor VIII in hemophilia

State-of-the-Art on Thrombotic Microangiopathies

- Describe the differential diagnosis of thrombotic microangiopathies
- Summarize the current guidelines for the diagnosis and management of thrombotic thrombocytopenic purpura (TTP)

State-of-the-Art on Fibrinolysis and Proteolysis

- Identify the effect thrombus structure and composition have on thrombolysis
- Evaluate how disturbances in the fibrinolysis pathway could be associated with an increased bleeding tendency

State-of-the-Art on Role of Hemostatic System in Cancer, Inflammation, and Immunity

- Describe the role of platelets in infections and sepsis
- Review the emerging data on fibrinolytic factors in cancer progression

State-of-the-Art on Arterial Thromboembolism

- Evaluate the data on the use of low-dose aspirin with dual antiplatelet therapy and the potential chemopreventive effect of low-dose aspirin against colorectal cancer
- Discuss the use of double and triple therapy for patients with atrial fibrillation and acute coronary syndrome/percutaneous coronary intervention

State-of-the-Art on Platelets and Megakaryocytes

- Summarize the associations among megakaryocyte, platelet biology, and inherited thrombocytopenias
- Identify the emerging data on the molecular and cellular mechanisms of Platelet GPIb α in thrombopoietin (TPO) generation and its implication in disease

Plenary - Von Willebrand factor: From Basic Science to Clinic

- Review the novel and emerging treatment options for von Willebrand disease
- Discuss the development of type-specific treatments for von Willebrand disease

MONDAY, JULY 13 SESSIONS

Plenary - Unmet Clinical Needs and Future Advances in VTE

- Review the association between venous thromboembolism (VTE) and Covid 19 infections
- Evaluate the effectiveness of machine learning (ML) in predicting venous thromboembolism (VTE)

State-of-the-Art on Diagnostics and OMICs

- Discuss the use of polygenic risk scores and the current data on genes suspected to be involved in the development of thrombosis
- Describe the use of high-throughput sequencing approaches and database mining for profiling the mutational landscape and diagnosing hereditary bleeding disorders

State-of-the-Art on Platelet Disorders and von Willebrand Disease

- Compare the current advances in clinical platelet function testing and genetic testing for platelet function
- Summarize the data on hemostasis, thrombosis, and the use of genotyping in Von Willebrand Disease

State-of-the-Art on Pediatrics

- Identify the risk factors for initial and recurrent strokes in pediatric patients
- Review the management of hemophilia and adverse events including the development of activity-neutralizing antibodies to Factor VIII in children

State-of-the-Art on Women's Health

- Evaluate the emerging data on thrombotic events and pregnancy including obstetric antiphospholipid syndrome
- Summarize the risks and benefits of direct oral anticoagulants (DOACs) for the prevention of venous thromboembolism (VTE) in women of reproductive age

State-of-the-Art on Coagulation & Natural Anticoagulants

- Discuss the pathophysiology of Factor X and Factor XII in coagulation
- Describe the diagnostic and therapeutic implications of HK cleavage and contact system inhibition in Alzheimer's disease

State-of-the-Art on Vascular Biology

- Review the current data and mechanisms of action of cell therapies targeting the endothelium
- Evaluate the strategies to target the vascular epithelium in sepsis

State-of-the-Art on Venous Thromboembolism

- Summarize the novel and emerging antithrombotic therapies and interventions for the management and prevention of venous thromboembolism (VTE)
- Explain the optimal use of direct oral anticoagulants (DOACs) in an emergency and unusual site venous thromboembolism

Plenary - Guidance or Organ-Specific Vascular Patterning

- Summarize the principles of angiogenic growth, arterial patterning, and marker expression
- Discuss the mechanisms governing vascular remodeling

Method of Participation

Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:

akhcme.com/akhcme/pages/ISTHEVAL

If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

Please claim your credit by August 31, 2020.



CME credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and International Society on Thrombosis and Haemostasis (ISTH). AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for Physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 4.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME.

Commercial Support

This activity is not supported by an educational grant.

FACULTY DISCLOSURES		
Name	Relationship	Commercial Interest
Rosanna Asselta	N/A	Nothing to Disclose
Cecilia Becattini	Consultant Speakers Bureau	Bayer; Bristol-Myers Squibb; Daiichi Sankyo Bayer; Bristol-Myers Squibb; Daiichi Sankyo
Wolfgang Bergmeier	N/A	Nothing to Disclose
Jan Beyer-Westendorf	Advisory Board Contracted Research Honoraria	Alexion; Bayer; Daiichi Sankyo; Portola Bayer; Boehringer Ingelheim; Daiichi Sankyo; Janssen; Pfizer; Portola Bayer; Daiichi Sankyo; Medscape; Pfizer; Portola; Rovi
Olivier Christophe	N/A	Nothing to Disclose
Alexander Cohen	Consultant Contracted Research Speakers Bureau	AbbVie; ACI Clinical; Aspen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Boston Scientific; CSL Behring; Daiichi Sankyo; GlaxoSmithKline; GLG; Guidepoint Global; Johnson and Johnson; Leo Pharma; Medscape; McKinsey; Navigant; ONO; Pfizer; Portola; Sanofi; Takeda; Temasek Capital; TRN Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Johnson and Johnson; Merck; Pfizer; Portola; Sanofi; Schering-Plough Aspen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Johnson and Johnson; Medscape; Pfizer; Portola
Anne Eichmann	N/A	Nothing to Disclose
Jeroen Eikenboom	Research Support; Principal Investigator	CSL Behring
Berend Isermann	N/A	Nothing to Disclose
Steve Kerrigan	N/A	Nothing to Disclose
Stavros Konstantinides	Consultant	Bayer; Bristol-Myers Squibb; Daiichi Sankyo; MSD; Pfizer
Sebastien Lacroix-Desmazes	N/A	Nothing to Disclose
Michele Lambert	N/A	Nothing to Disclose
Lai Heng Lee	Honoraria	Sanofi
Peter Lenting	Consultant Contracted Research Speakers Bureau Stock	NovalGen Catalyst Biosciences; SOBI Bayer; Catalyst Biosciences; Chugai; CSL Behring; LFB; Roche; Shire; Sobi; Spark Therapeutics Laelaps Therapeutics
Marcel Levi	N/A	Nothing to Disclose
Renato Lopes	Consultant Grant Support	Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Medtronic; Merck; Pfizer; Portola; Sanofi Bristol-Myers Squibb; GlaxoSmithKline; Medtronic; Pfizer; Sanofi
José López	N/A	Nothing to Disclose
Peetra Magnusson	N/A	Nothing to Disclose
Federico Mingozzi	Salary Stock	Spark Therapeutics, a Roche company Roche
Luigi Naldini	Contracted Research Royalty	Bioverativ/Sanofi San Raffaele Telethon Institute
Amit Nathwani	N/A	Nothing to Disclose
Heyu Ni	Contracted Research; Royalty; Salary	CCOA Therapeutics Inc.
Ulrike Nowak-Gottl	N/A	Nothing to Disclose
Ingrid Pabinger	Advisory Board Honoraria Research Support	Bayer; Biotest; CSL Behring; Novo Nordisk; Pfizer; Takeda; Bayer; Biotest; CSL Behring; Diagnostica Stago, Inc.; Novo Nordisk; Pfizer; Takeda; Biotest; CSL Behring; Novo Nordisk; Takeda
Carlo Patrono	Consultant	Acticor Biotech; Amgen; Bayer; GlaxoSmithKline; Tremeau; Zambon

Steven Pipe	Consultant	Apcintex; Bayer; BioMarin; Catalyst Biosciences; CSL Behring; HEMA Biologics; Freeline; Genentech/Roche; Novo Nordisk; Pfizer; Sangamo Therapeutics; Sanofi; Takeda; Spark Therapeutics; uniQure
Marie Ranson	N/A	Nothing to Disclose
Hana Raslova	N/A	Nothing to Disclose
Giuseppe Remuzzi	N/A	Nothing to Disclose
Nicoletta Riva	N/A	Nothing to Disclose
Florence Sabatier	N/A	Nothing to Disclose
Heribert Schunkert	Honoraria Institutional Grant Travel Grant	Amgen; AstraZeneca; Bayer Vital GmbH; Boehringer Ingelheim; Brahms; Bristol-Myers Squibb; Daiichi-Sankyo; Medtronic; Merck Sharp & Dohme Corp; Novartis; Pfizer; sanofi-aventis U.S. LLC; Servier; Synlab AstraZeneca Vifor Pharma
John Semple	N/A	Nothing to Disclose
Oonagh Shannon	N/A	Nothing to Disclose
Nicholas Smith	N/A	Nothing to Disclose
Evi Stavrou	N/A	Nothing to Disclose
Sidney Strickland	N/A	Nothing to Disclose
Douglas Vaughan	N/A	Nothing to Disclose
John Weisel	N/A	Nothing to Disclose
Guy Young	Consultant Contracted Research	BioMarin; Freeline; Genentech/Roche; Grifols; Kedrion; Novo Nordisk; Sanofi Genzyme; Spark Therapeutics; Takeda; UniQure Genentech/Roche; Grifols; Takeda
X. Long Zheng	Co-founder Consultant Speakers Bureau	Clotsolution, Inc. Sanofi Genzyme; Takeda Alexion; Sanofi Genzyme
PLANNER DISCLOSURES		
Dorothy Caputo, MA, BSN, RN - Director of Accreditations	N/A	Nothing to Disclose
AKH Inc Staff, Planners and Reviewers	N/A	Nothing to Disclose
ISTH Staff and Planners	N/A	Nothing to Disclose

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.